🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the effort against increasingly resistant strains of the infection, according to health experts.

An International Public Health Issue

Gonorrhoea infections are escalating worldwide, with figures suggesting more than 82 million instances per year. Particularly high rates are seen in the African continent and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune advancement in the reality of rising global incidence, the spread of superbugs and the very limited available drugs currently available.”

Health officials are particularly alarmed about the increase in treatment-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance found that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Secure Clearance

Zoliflodacin, also known as Nuzolvence, was authorized by the US Food and Drug Administration in recent days for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists believe that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This treatment, which is employed against urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment emerged from a unique collaborative effort for medication research. The charitable organization GARDP collaborated with the drug firm its industry partner to develop it.

“This authorization signifies a significant shift in the therapy of superbug gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Data and Global Access

Based on findings detailed in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of cases of the STI. This places it at an equal footing with the typical regimen, which uses an injection and a pill. The research enrolled hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the authority to license and sell the drug in many low-income and middle-income countries.

Medical professionals treating patients have expressed hope. Access to a single-dose, oral treatment of this kind is hailed as a "game-changer" for gonorrhoea control. This is considered crucial to alleviate the strain of the illness for people and to prevent the spread of highly drug-resistant gonorrhoea globally.